Sequential proleukin(rIL-2) by continuous infusion with cisplatin and cyclophosphamide in patients with unresectable ovarian cancer

Eur J Cancer. 1991;27(6):804. doi: 10.1016/0277-5379(91)90194-i.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Combined Modality Therapy
  • Drug Evaluation
  • Female
  • Humans
  • Interleukin-2 / adverse effects*
  • Ovarian Neoplasms / therapy*
  • Recombinant Proteins / adverse effects

Substances

  • Interleukin-2
  • Recombinant Proteins